invoX CEO Ben Toogood (L) and F-star CEO Eliot Forster
July 8, 2022 09:17 AM EDTUpdated 03:02 PM
Deals
Bioregnum

A por­trait of a biotech buy­out deal in sav­age times: turn­ing a $15.50 of­fer in­to a $7.12 deal

Back last No­vem­ber, the once high-fly­ing F-star was hurt­ing, bad. Its share price had been crushed and the CEO, Eliot Forster of Im­muno­core fame, had …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times